HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Design and optimization of aspartate N-acetyltransferase inhibitors for the potential treatment of Canavan disease.

Abstract
Canavan disease is a fatal neurological disorder caused by defects in the metabolism of N-acetyl-l-aspartate (NAA). Recent work has shown that the devastating symptoms of this disorder are correlated with the elevated levels of NAA observed in these patients, caused as a consequence of the inability of mutated forms of aspartoacylase to adequately catalyze its breakdown. The membrane-associated enzyme responsible for the synthesis of NAA, aspartate N-acetyltransferase (ANAT), has recently been purified and examined (Wang et al., Prot Expr Purif. 2016;119:11). With the availability, for the first time, of a stable and soluble form of ANAT we can now report the identification of initial inhibitors against this biosynthetic enzyme, obtained from the screening of several focused compound libraries. Two core structures of these moderate binding compounds have subsequently been optimized, with the most potent inhibitors in these series possessing sub-micromolar inhibition constants (Ki values) against ANAT. Slowing the production of NAA via the inhibition of ANAT will lower the elevated levels of this metabolite and can potentially serve as a treatment option to moderate the symptoms of Canavan disease.
AuthorsBharani Thangavelu, Vinay Mutthamsetty, Qinzhe Wang, Ronald E Viola
JournalBioorganic & medicinal chemistry (Bioorg Med Chem) Vol. 25 Issue 3 Pg. 870-885 (02 01 2017) ISSN: 1464-3391 [Electronic] England
PMID28007430 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2016 Elsevier Ltd. All rights reserved.
Chemical References
  • Enzyme Inhibitors
  • Acetyltransferases
  • aspartate N-acetyltransferase
Topics
  • Acetyltransferases (antagonists & inhibitors, metabolism)
  • Canavan Disease (drug therapy, metabolism)
  • Dose-Response Relationship, Drug
  • Drug Design
  • Enzyme Inhibitors (chemical synthesis, chemistry, pharmacology)
  • Humans
  • Molecular Structure
  • Structure-Activity Relationship

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: